Table 1.
Comparative activity of ceftolozane/tazobactam against selected U.S. clinical Gram-negative bacilli
| MIC50 / MIC90 (mg/L)
| |||||
|---|---|---|---|---|---|
| Organism | Ceftolozane/tazobactam | Ceftazidime | Cefepime | Meropenem | Piperacillin/tazobactam |
| Pseudomonas aeruginosa | 1/4 | 2/32 | 4/16 | 0.5/8 | 8/>64 |
| Escherichia coli | 0.25/0.5 | 0.12/2 | ≤0.5/4 | ≤0.06/≤0.06 | 2/8 |
| Klebsiella spp. | 0.25/2 | 0.12/32 | ≤0.5/8 | ≤0.06/≤0.06 | 4/>64 |
| Enterobacter spp. | 0.25/8 | 0.25/>32 | ≤0.5/2 | ≤0.06/≤0.06 | 2/64 |
| Serratias spp. | 0.5/1 | 0.12/0.5 | ≤0.5/≤0.5 | ≤0.06/≤0.06 | 2/4 |
| Proteus mirabilis | 0.5/0.5 | 0.06/0.06 | ≤0.5/≤0.5 | ≤0.06/≤0.06 | ≤0.5/1 |
| Citrobacter spp. | 0.25/8 | 0.25/>32 | ≤0.5/1 | ≤0.06/≤0.06 | 2/64 |
Notes: MIC breakpoint for ceftolozane/tazobactam has not been established. Data from Sader et al.29
Abbreviations: MIC, minimum inhibitory concentration.